Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients ...

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of ...

An expert discusses how choosing between triplet and quadruplet regimens for transplant-ineligible multiple myeloma depends on patient fitness, disease risk, and treatment tolerability. He highlights ...

England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.